Boston Scientific (NYSE:BSX) Sets New 1-Year Low Following Analyst Downgrade

Boston Scientific Corporation (NYSE:BSX) shares hit a new 52-week low on Tuesday after Stifel Nicolaus lowered their price target on the stock from $90.00 to $85.00. Stifel Nicolaus currently has a buy rating on the stock. Boston Scientific traded as low as $60.05 and last traded at $61.4330, with a volume of 2552167 shares traded. The stock had previously closed at $60.99.

BSX has been the topic of a number of other reports. Citigroup lowered their target price on shares of Boston Scientific from $94.00 to $87.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Mizuho lowered their target price on shares of Boston Scientific from $115.00 to $90.00 and set an “outperform” rating on the stock in a report on Monday, April 13th. Jefferies Financial Group restated a “buy” rating on shares of Boston Scientific in a report on Monday, March 16th. Wells Fargo & Company lowered their target price on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Finally, Needham & Company LLC restated a “buy” rating and set a $97.00 target price on shares of Boston Scientific in a report on Monday, March 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $102.59.

Insider Activity at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.34% of the stock is currently owned by corporate insiders.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Positive clinical readout for WATCHMAN FLX (CHAMPION?AF) supports longer?term upside and remains the key fundamental bull case for growth in electrophysiology and stroke?prevention procedures. QuiverQuant: BSX slips as investors stay cautious
• Positive Sentiment: Several sell?side firms continue to rate BSX positively (Buy/Overweight), which provides analyst support even as some targets are trimmed — e.g., Piper Sandler reaffirmed Overweight after Champion?AF. InsiderMonkey: Piper Sandler view
• Neutral Sentiment: Analyst price?target adjustments have been modest — Stifel cut its PT to $85 (still a Buy) and Truist trimmed its PT to $90 while keeping a Buy rating — signaling confidence in the story but slightly lower near?term estimates. Benzinga: Stifel PT cut
• Negative Sentiment: Broad legal headline risk: multiple law firms have filed/solicited investors for a securities?class action tied to disclosures from July 2025–Feb 2026, and there is a May 4, 2026 lead?plaintiff deadline — these notices increase headline-driven volatility and potential future litigation costs. GlobeNewswire: Portnoy Law Firm class action
• Negative Sentiment: Near?term execution risk and pre?earnings de?risking: investors are cautious ahead of BSX’s quarterly results (scheduled next week), and recent coverage notes cite uncertainty about how trial readouts convert to near?term procedure growth and reimbursement. This is likely contributing to selling pressure. QuiverQuant: Pre?earnings caution analysis

Institutional Investors Weigh In On Boston Scientific

A number of institutional investors have recently modified their holdings of BSX. Brighton Jones LLC boosted its position in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares during the period. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the second quarter valued at about $26,000. Main Street Financial Solutions LLC boosted its position in shares of Boston Scientific by 35.3% in the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock valued at $812,000 after acquiring an additional 1,971 shares during the period. Ieq Capital LLC boosted its position in shares of Boston Scientific by 97.0% in the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after acquiring an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC boosted its position in shares of Boston Scientific by 56.2% in the second quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after acquiring an additional 2,556 shares during the period. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

The stock’s 50-day moving average price is $69.34 and its 200-day moving average price is $86.58. The company has a market cap of $91.43 billion, a P/E ratio of 31.71, a PEG ratio of 0.99 and a beta of 0.78. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. Boston Scientific’s quarterly revenue was up 15.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 3.45 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.